Vaccine candidate against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Routes of administration | Intramuscular |
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
Stemirna COVID-19 vaccine is a COVID-19 vaccine candidate developed by Stemirna Therapeutics.[1][2]
References
[edit]- ^ "Randomized, double-blind, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of mRNACOVID-19 vaccine in healthy susceptible populations aged 18 years and older people". Chinese Clinical Trial Registry (ChiCTR). Archived from the original on 15 May 2021. Retrieved 15 May 2021.
- ^ Clinical trial number NCT05144139 for "A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above" at ClinicalTrials.gov
![](https://upload.wikimedia.org/wikipedia/commons/thumb/3/32/Scholia_logo.svg/40px-Scholia_logo.svg.png)
Scholia has a profile for Stemirna COVID-19 vaccine (Q110269793).
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|